RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2022 May 18

PMID 35583609

Authors

Wout de Mey

Arthur Esprit

Kris Thielemans

Karine Breckpot

Lorenzo Franceschini

Affiliations

Soon will be listed here.

Abstract

Recent advances in the manufacturing, modification, purification, and cellular delivery of ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a broad array of applications. The approval of two SARS-CoV-2-targeting mRNA-based vaccines has highlighted the advances of this technology. Offering rapid and straightforward manufacturing, clinical safety, and versatility, this paves the way for RNA therapeutics to expand into cancer immunotherapy. Together with ongoing trials on RNA cancer vaccination and cellular therapy, RNA therapeutics could be introduced into clinical practice, possibly stewarding future personalized approaches. In the present review, we discuss recent advances in RNA-based immuno-oncology together with an update on ongoing clinical applications and their current challenges.

Citing Articles

Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy.

Laila U, An W, Xu Z Front Immunol. 2024; 15:1448489.

PMID: 39654897 PMC: 11625737. DOI: 10.3389/fimmu.2024.1448489.

Lipid-Based Nanocarriers for Targeted Gene Delivery in Lung Cancer Therapy: Exploring a Novel Therapeutic Paradigm.

Beigi A, Naghib S, Matini A, Tajabadi M, Mozafari M Curr Gene Ther. 2024; 25(2):92-112.

PMID: 38778601 DOI: 10.2174/0115665232292768240503050508.

Colorectal Cancer Immunotherapy: State of the Art and Future Directions.

Cornista A, Giolito M, Baker K, Hazime H, Dufait I, Datta J Gastro Hep Adv. 2023; 2(8):1103-1119.

PMID: 38098742 PMC: 10721132. DOI: 10.1016/j.gastha.2023.09.007.

Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines.

Hargrave A, Mustafa A, Hanif A, Tunio J, Hanif S Vaccines (Basel). 2023; 11(11).

PMID: 38005965 PMC: 10675687. DOI: 10.3390/vaccines11111633.

Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists.

Cirella A, Bolanos E, Luri-Rey C, Di Trani C, Olivera I, Gomis G Mol Ther Nucleic Acids. 2023; 33:668-682.

PMID: 37650116 PMC: 10462790. DOI: 10.1016/j.omtn.2023.07.026.

References

Lima S, Chipman L, Nicholson A, Chen Y, Yee B, Yeo G . Short poly(A) tails are a conserved feature of highly expressed genes. Nat Struct Mol Biol. 2017; 24(12):1057-1063. PMC: 5877826. DOI: 10.1038/nsmb.3499. View

Bajan S, Hutvagner G . RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. Cells. 2020; 9(1). PMC: 7016530. DOI: 10.3390/cells9010137. View

Mayor M, Yang N, Sterman D, Jones D, Adusumilli P . Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg. 2015; 49(5):1324-33. PMC: 4851162. DOI: 10.1093/ejcts/ezv371. View

Wei J, Gilboa E, Calin G, Heimberger A . Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment. Front Oncol. 2021; 11:682129. PMC: 8438301. DOI: 10.3389/fonc.2021.682129. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Dorrie J, Schaft N, Schuler G, Schuler-Thurner B . Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update. Pharmaceutics. 2020; 12(2). PMC: 7076681. DOI: 10.3390/pharmaceutics12020092. View

Galaine J, Borg C, Godet Y, Adotevi O . Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel). 2015; 3(3):490-502. PMC: 4586463. DOI: 10.3390/vaccines3030490. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Liu M . A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel). 2019; 7(2). PMC: 6631684. DOI: 10.3390/vaccines7020037. View

10.

Henderson J, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N . Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap Analog by In Vitro Transcription. Curr Protoc. 2021; 1(2):e39. DOI: 10.1002/cpz1.39. View

11.

Mello C, Conte Jr D . Revealing the world of RNA interference. Nature. 2004; 431(7006):338-42. DOI: 10.1038/nature02872. View

12.

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

13.

Young Chung J, Thone M, Kwon Y . COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2020; 170:1-25. PMC: 7759095. DOI: 10.1016/j.addr.2020.12.011. View

14.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

15.

Berber B, Aydin C, Kocabas F, Guney-Esken G, Yilancioglu K, KaradaG-Alpaslan M . Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics. Gene Ther. 2020; 28(6):290-305. PMC: 7734466. DOI: 10.1038/s41434-020-00209-7. View

16.

Etxeberria I, Bolanos E, Quetglas J, Gros A, Villanueva A, Palomero J . Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8 T Cells. Cancer Cell. 2019; 36(6):613-629.e7. DOI: 10.1016/j.ccell.2019.10.006. View

17.

Rajan T, Gugliandolo A, Bramanti P, Mazzon E . In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Int J Mol Sci. 2020; 21(18). PMC: 7556036. DOI: 10.3390/ijms21186514. View

18.

Filin I, Kitaeva K, Rutland C, Rizvanov A, Solovyeva V . Recent Advances in Experimental Dendritic Cell Vaccines for Cancer. Front Oncol. 2021; 11:730824. PMC: 8495208. DOI: 10.3389/fonc.2021.730824. View

19.

Bloom K, van den Berg F, Arbuthnot P . Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2020; 28(3-4):117-129. PMC: 7580817. DOI: 10.1038/s41434-020-00204-y. View

20.

Lundstrom K . Self-Amplifying RNA Viruses as RNA Vaccines. Int J Mol Sci. 2020; 21(14). PMC: 7404065. DOI: 10.3390/ijms21145130. View